Table 1.
Current status of research and development of COVID-19 therapeutic drugs targeting IL-6.
| Drug name | R&D code | The first R&D company | Targets (combined with simplified targets) | The world's highest R&D stage | Indications |
|---|---|---|---|---|---|
| Tocilizumab | MR16-1; R-1569; RG-1569; hPM-1; RO-4877533 | Roche | IL-6 receptor antagonist (IL-6R); IL-6 receptor modulator (IL-6R) | Listed stage | Adult Still's disease; autoimmune encephalomyelitis; giant lymphadenopathy; chronic lymphocytic leukemia; COVID-19; familial mediterranean fever; juvenile rheumatoid arthritis; motor neuron disease ; osteoarthritis; polymyalgia rheumatica; pulmonary hypertension; rheumatoid arthritis; systemic lupus erythematosus; toxicity; viral pneumonia |
| Siltuximab | CNTO-328 | Johnson&Johnson | Heat shock protein inhibitor (HSP); IL-6 receptor antagonist (IL-6R) | Listed stage | Megalymphadenopathy; chronic lymphocytic leukemia; COVID-19; pneumonia |
| Levilimab | BCD-089 | Biocad Ltd | IL-6 receptor antagonist (IL-6R) | Listed stage | COVID-19; rheumatoid arthritis |
| Olokizumab | CDP-6038 | UCB | IL-6 receptor antagonist (IL-6R) | Listing application | COVID-19; rheumatoid arthritis |
| Emiplacel | PLX-1; PLX-R18 | Pluristem Therapeutics Inc | IL-6 receptor agonist (IL-6R) | Phase III clinical stage | Aplastic anemia; autoimmune disease; bone injury; bone marrow transplantation; heart failure; COVID-19; diabetic foot ulcer; graft-versus-host disease; hematopoietic stem cell transplantation; inflammatory bowel disease; intermittent claudication; interstitial lung diseases; ischemia; lung injury; multiple sclerosis; muscle injury; muscular atrophy; muscular dystrophy; neurological disorders; neuropathic pain; peripheral vascular disease; preeclampsia; pulmonary fibrosis; radiation sickness; respiratory distress syndrome symptoms; skin burns; tendon injuries; thromboangiitis obliterans; wound healing |
| Emvododstat | PTC-299; PTC-VG; PTC-VH; PTC-VJ; PTC-VK; PTC-WS | PTC Therapeutics Inc | Dihydroorotate dehydrogenase inhibitor (DHODH); IL-6 receptor antagonist (IL-6R); VEGF receptor antagonist (VEGFR) | Phase III clinical stage | Acute myeloid leukemia; COVID-19; myelodysplastic syndromes |
| Clazakizumab | ALD-518;BMS-945429 | Alder | IL-6 receptor antagonist (IL-6R) | Phase III clinical stage | COVID-19; kidney transplant rejection; lung failure; organ transplant rejection; respiratory distress syndrome |
| Sirukumab | CNTO-136 | Johnson&Johnson | IL-6 receptor antagonist (IL-6R) | Phase III clinical stage | COVID-19; major depressive disorder |
| MP-1032 | MP-1000;MP-1000 program; MP-1031;MP-1032 | MetrioPharm AG | Catalase stimulator (CAT); Interleukin-1 ligand inhibitor (IL-1); Interleukin-6 ligand inhibitor (IL-6); Interleukin-8 ligand inhibitor (IL-8); Superoxide dismutase stimulator (SOD); TNF alpha ligand inhibitor (TNF-α) | Phase Ⅱ clinical stage | COVID-19; inflammatory diseases; multiple sclerosis; psoriasis |
| Amilo-5MER | —— | Galmed Pharmaceuticals Ltd | Apolipoprotein B modulator (APOB); IL-6 receptor antagonist (IL-6R); Serum amyloid A protein modulator (SAA); Transthyretin modulator (TTR) | Phase Ⅰ clinical stage | COVID-19; crohn's disease; inflammatory bowel disease; multiple sclerosis; psoriasis; respiratory distress syndrome; rheumatoid arthritis; ulcerative colitis |
| KSI-501 | KSI-501; KSI-501p;OG-2072 | Kodiak Sciences Inc | Interleukin-6 ligand inhibitor (IL-6); VEGF ligand inhibitor (VEGF) | Preclinical research stage | COVID-19; diabetic macular edema; diabetic retinopathy; uveitis; wet age-related macular degeneration |
| Tocilizumab biosimilar | BP-08 | Curateq Biologics Pvt Ltd | IL-6 receptor modulator (IL-6R) | Preclinical research stage | COVID-19 |
| ACE2-Fc-anti-IL-6R scfv fusion protein | —— | Shanghai Keqi Pharmaceutical Technology Co Ltd | COVID-19 spike glycoprotein inhibitor; IL-6 receptor antagonist (IL-6R) | Preclinical research stage | COVID-19 |
| rIFN-alpha 14 | —— | ILC Therapeutics Ltd | CXC10 chemokine ligand inhibitor (CXCL10); CXC5 chemokine ligand inhibitor (CXCL5); Growth regulated protein alpha ligand inhibitor (CXCL1); Interferon alpha 14 ligand (IFNA14); Interferon gamma receptor agonist (IFNGR); Interleukin 17A ligand inhibitor (IL-17A); Interleukin 17F ligand inhibitor (IL-17F); Interleukin-6 ligand inhibitor (IL-6); Interleukin-8 ligand inhibitor (IL-8); Monocyte chemotactic protein 1 ligand inhibitor (CCL2); NK cell receptor agonist (KIR2DL4); RANTES ligand (CCL5); T cell receptor agonist (TCR) | Preclinical research stage | COVID-19; respiratory distress syndrome |
*The source of the data is from the global drug research and development database of the one-stop retrieval platform of pharnexcloud (https://www.pharnexcloud.com).